Gluetacs Therapeutics Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 20

Employees

  • Latest Deal Type
  • Series A

  • Investors
  • 12

Gluetacs Therapeutics General Information

Description

Developer of targeted protein degradation technologies designed for oncology and immunotherapy. The company offers molecular glues, bifunctional degraders, and AI-powered drug discovery platforms, providing healthcare providers and the pharmaceutical sector with specialized hardware and oral small-molecule therapies for refractory cancers and autoimmune diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Building 20, Lane 218, Haiji Sixth Road
  • Pudong New Area
  • Shanghai, 201306
  • China
+86 021
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • Building 20, Lane 218, Haiji Sixth Road
  • Pudong New Area
  • Shanghai, 201306
  • China
+86 021

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Gluetacs Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Early Stage VC (Series A) 04-Jan-2024 Completed Generating Revenue
5. Early Stage VC 03-Jul-2022 Completed Generating Revenue
4. Early Stage VC 11-Nov-2021 Completed Generating Revenue
3. Early Stage VC 22-Mar-2021 Completed Generating Revenue
2. Accelerator/Incubator 01-Dec-2020 Completed Startup
1. Seed Round 01-Nov-2020 Completed Startup
To view Gluetacs Therapeutics’s complete valuation and funding history, request access »

Gluetacs Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Gluetacs Therapeutics Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
Gortune Investment Venture Capital Minority
Huangpu Biomedical Industry Investment Fund Growth/Expansion Minority
Leading Capital Company Asset Manager Minority
Shanghai Sinan Yuanke Private Equity Fund Management Growth/Expansion Minority
In Capital Venture Capital Minority
You’re viewing 5 of 12 investors. Get the full list »

Gluetacs Therapeutics FAQs

  • When was Gluetacs Therapeutics founded?

    Gluetacs Therapeutics was founded in 2020.

  • Where is Gluetacs Therapeutics headquartered?

    Gluetacs Therapeutics is headquartered in Shanghai, China.

  • What is the size of Gluetacs Therapeutics?

    Gluetacs Therapeutics has 20 total employees.

  • What industry is Gluetacs Therapeutics in?

    Gluetacs Therapeutics’s primary industry is Biotechnology.

  • Is Gluetacs Therapeutics a private or public company?

    Gluetacs Therapeutics is a Private company.

  • What is Gluetacs Therapeutics’s current revenue?

    The current revenue for Gluetacs Therapeutics is .

  • How much funding has Gluetacs Therapeutics raised over time?

    Gluetacs Therapeutics has raised $22.5M.

  • Who are Gluetacs Therapeutics’s investors?

    Gortune Investment, Huangpu Biomedical Industry Investment Fund, Leading Capital Company, Shanghai Sinan Yuanke Private Equity Fund Management, and In Capital are 5 of 12 investors who have invested in Gluetacs Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process